Avalo Therapeutics Cash from Financing (TTM) Analysis

Avalo Therapeutics Inc (AVTX)

12.75 -0.75 (-5.56%) USD | NASDAQ | May 08, 09:55

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	25.04M
September 30, 2023	25.12M
June 30, 2023	14.43M
March 31, 2023	-0.951M
December 31, 2022	-14.70M
September 30, 2022	-14.70M
June 30, 2022	32.94M
March 31, 2022	68.94M
December 31, 2021	106.76M
September 30, 2021	106.89M
June 30, 2021	59.24M
March 31, 2021	73.51M
December 31, 2020	44.78M
September 30, 2020	44.72M
June 30, 2020	48.23M
March 31, 2020	12.84M
December 31, 2019	12.56M
September 30, 2019	18.59M
June 30, 2019	18.92M

Date	Value
March 31, 2019	18.86M
December 31, 2018	10.40M
September 30, 2018	4.249M
June 30, 2018	-0.1963M
March 31, 2018	3.980M
December 31, 2017	3.737M
September 30, 2017	3.761M
June 30, 2017	4.743M
March 31, 2017	-0.4602M
December 31, 2016	-1.426M
September 30, 2016	19.94M
June 30, 2016	18.57M
March 31, 2016	18.77M
December 31, 2015	19.60M
September 30, 2015	-1.821M
June 30, 2015	21.81M
March 31, 2015	23.92M
December 31, 2014	23.86M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-14.70M

Minimum

Sep 2022

106.89M

Maximum

Sep 2021

35.96M

Average

25.12M

Median

Sep 2023

Cash from Financing (TTM) Benchmarks